Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Stem Cells Translational Medicine|July 17, 2023
Progress in Stem Cells-Based Replacement Therapy for Retinal Pigment Epithelium: In Vitro Differentiation to In Vivo DeliverySantosh Gupta, Lyubomyr Lytvynchuk, Taras Ardan, et al.
The American Journal of Pathology|February 2, 2011
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancerPaula Vainio, Santosh Gupta, Kirsi Ketola, et al.
Plos One|March 3, 2011
GTI: a novel algorithm for identifying outlier gene expression profiles from integrated microarray datasetsJohn Patrick Mpindi, Henri Sara, Saija Haapa-Paananen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2023
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate CancerSantosh Gupta, Susan Halabi, Qian Yang, et al.
Prostate Cancer and Prostatic Diseases|April 1, 2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)Santosh Gupta, Siyuan Guo, Susan Halabi, et al.
Cancer Medicine|July 5, 2019
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancerMatthew D Tucker, Jason Zhu, Daniele Marin, et al.
JCI Insight|November 4, 2025
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancerOssian Longoria, Jan Rekowski, Santosh Gupta, et al.
Genes, Chromosomes & Cancer|November 10, 2019
Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancerSantosh Gupta, Daniel H Hovelson, Gabor Kemeny, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
<i>LRP1B</i> mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer typesLandon C Brown, Matthew D Tucker, Ramy Sedhom, et al.
Plos One|May 29, 2019
Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancerAndrew J Armstrong, Santosh Gupta, Patrick Healy, et al.
Pageof 6